Alterity Therapeutics FY26 net loss widens to $23.4 million; R&D expenses rise 22% to A$17.63 million

• Alterity Therapeutics posted a net loss of U.S.$23.4 million, widening from U.S.$12.1 million in the prior year.
• Operating cash outflow widened to U.S.$22.5 million from U.S.$11.5 million; cash and cash equivalents rose to A$37.32 million.
• Research and development expenses climbed 22% to A$17.63 million; general and administrative costs jumped 92% to A$10.53 million.
• Interest income rose to A$1.72 million from A$446,291; other income included A$3.61 million tied to the R&D Tax Incentive.
• An issued capital consolidation of 50-to-1 took effect on May 29, 2026; unexercised options totaled 66,200,000 at June 30.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-029135), on August 28, 2026, and is solely responsible for the information contained therein.